Our Library on T Cell-based Immunotherapies for Cancer and Infectious Diseases
2024
GIHEP 2024
Luber A, et al.
The potential role for a novel class, a Checkpoint Modifier, in the functional cure of CHB: the science and clinical data from VRON-0200Vaccines
Mohammadi M, et al.
Preclinical Immunogenicity and Efficacy Studies for Therapeutic Vaccines for Human Papillomavirus-Type-16-Associated CancerEASL 2024, Poster # LBP-018
Gane EJ, et al.
Promising first-in-human, first-in-class, Phase 1b immunogenicity data of VRON-0200, a novel checkpoint modifier containing immunotherapy, for HBV functional cureAPASL 2024, Oral # O-0138
Wong, GL et al.
First-in-Human, First-in-Class, Phase 1B Preliminary Safety Data of VRON-0200, a Novel Checkpoint Modifier Containing Immunotherapy, for HBV Functional Cure2023
SITC 2023, Poster #454
Currie S, et al.
Checkpoint Modification of Early T cell Activation Provides Enhanced Anti-Tumor Activity and Survival Benefits in a Fast-Growing Preclinical Tumor Challenge ModelEASL 2023, Poster #TOP-107
Ertl HCJ, et al.
Intrahepatic CD8+ T cells correlate with significant declines in HBV viral load and S antigen following a single vaccination with VRON-0200 in an AAV mouse modelESMO TAT 2023, Poster #36P
Currie S, et al.
Therapeutic Vaccination With HPV-16 Oncoproteins Fused Into a Checkpoint Modifier of Early T-cell Activation Protects Against HPV-associated Tumors in a Preclinical Model2022
ID Week 2022, Oral #869
Ertl HCJ, et al.
Novel checkpoint modifier lowers T cell activation threshold and enhances and broadens vaccine-induced responses to chronic viral infectionsFront Immunol, DOI: 10.3389/fimmu.2022.985382
Ertl HCJ, et al.
Restricting use of adenovirus vector-based COVID vaccines could endanger public and global healthFront Public Health, DOI: 10.3389/fpubh.2022.929445
Ertl HCJ, et al.
Back to the future: Can vaccines win the long-term fight against COVID-19?ASGCT, Abstract #0490
Luber A, et al.
Novel Early Checkpoint Modifier Demonstrates Broadened and Enhanced CD8+ T Cell Responses Across Multiple Preclinical StudiesAPASL, Abstract #OP-0685
Hasanpourghadi M, et al.
Preclinical Immunogenicity and Efficacy of VRON-0200: A Novel Therapeutic Vaccine for Potential Functional Cure Therapies in Patients with Chronic HBVESMO TAT, Abstract #143
Luber A, et al.
Checkpoint Modification of BTLA-HVEM-LIGHT Signaling by HSV-1 Glycoprotein D (gD) Improves Vaccine-Induced CD8 T Cell Responses in Pre-clinical Cancer ModelsBioRxiv, DOI: 10.1101/2022.02.23.481620
Novikov M, et al.
Pre-clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-22021
Virol J, PMID: 34876153
Hasanpourghadi M, et al.
Hepatitis B virus polymerase-specific T cell epitopes shift in a mouse model of chronic infectionEASL, Abstract #OS-2478
Hasanpourghadi M, et al.
VRON-0200, a Therapeutic HBV Vaccine With an Intrinsic Checkpoint Inhibitor, Elicits Broad CD8+ T Cell Responses and Sustained Antiviral Declines in Preclinical StudiesTrends Biochem Sci, PMID: 33810926
Hasanpourghadi M, et al.
COVID-19 Vaccines Based on Adenovirus Vectors2020
AASLD, Poster #0826
Hasanpourghadi M, et al.
Glycoprotein D, a Checkpoint Inhibitor of Early T cell Activation, Broadens HBV-specific CD8+ T cell Responses and Produces HBV Viral Load Declines in Preclinical StudiesEASL, Poster #1303
Hasanpourghadi M, et al.
Immunogenicity and Efficacy of an HBV Vaccine with an Intrinsic Checkpoint InhibitorASCO-SITC Clinical Immuno-Oncology Symposium, Poster #71
Xiang ZQ, et al.
Glycoprotein D, a Checkpoint Inhibitor of Early T cell Activation, Improves Immunogenicity and Efficacy of an HPV-16 Vaccine in Preclinical Studies2014
J Immunol, PMID: 25024391
Zhang Y and Ertl HCJ
The Effect of Adjuvanting Cancer Vaccines with Herpes Simplex Virus Glycoprotein D on Melanoma-Driven CD8+ T Cell Exhaustion